Arrowhead Pharmaceuticals
Clinical trials sponsored by Arrowhead Pharmaceuticals, explained in plain language.
-
New shot could tame stubborn high cholesterol
Disease control Recruiting nowThis study tests an experimental drug called ARO-DIMERPA in 78 adults with mixed hyperlipidemia (high cholesterol and triglycerides). The drug is given as a shot under the skin, and researchers are checking if it is safe and how well it lowers fats in the blood. The trial is stil…
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
New shot every 3 months could stop pancreatitis in people with Sky-High triglycerides
Disease control Recruiting nowThis phase 3 trial tests a drug called plozasiran in 288 adults with severe hypertriglyceridemia (very high blood fats) who have had at least two pancreatitis attacks. Participants receive either the drug or a placebo every three months. The main goal is to see if the drug can pr…
Phase: PHASE3 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New obesity drug ARO-INHBE enters human trials
Disease control Recruiting nowThis study tests an experimental drug called ARO-INHBE in 180 adults with obesity, some of whom also have type 2 diabetes. The drug is given as a shot under the skin, either alone or combined with the existing weight-loss drug tirzepatide. The main goal is to check safety and how…
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New injection aims to tackle Alzheimer's at its roots
Disease control Recruiting nowThis study tests a new drug called ARO-MAPT-SC in healthy people and those with early Alzheimer's. The goal is to check if it is safe and how the body processes it. Participants receive either the drug or a placebo by injection under the skin. The trial is still in early stages, …
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New shot aims to slash sky-high cholesterol in rare genetic disease
Disease control Recruiting nowThis study tests a new medicine called zodasiran in people aged 12 and older who have a rare genetic condition that causes extremely high cholesterol (homozygous familial hypercholesterolemia). The goal is to see if the drug can safely lower bad cholesterol levels over 12 months.…
Phase: PHASE3 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug shows promise for controlling dangerous fat levels in blood
Disease control Recruiting nowThis study tests the long-term safety and effectiveness of a drug called plozasiran in adults with very high triglycerides (a type of fat in the blood). About 869 people who completed earlier studies will receive injections every 3 months for 2 years. The goal is to see if the dr…
Phase: PHASE3 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New RNA injection targets obesity and diabetes in early trial
Disease control Recruiting nowThis early-stage study tests an experimental drug called ARO-ALK7 in 138 adults with obesity, some of whom also have type 2 diabetes. The drug is given as an injection and aims to help with weight loss and blood sugar control. The main goal is to check safety and how the body pro…
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug offers hope for rare, severe high triglyceride conditions
Disease control AVAILABLEThis program gives adults and adolescents with familial chylomicronemia syndrome (FCS) and adults with severe hypertriglyceridemia (SHTG) access to an experimental drug called plozasiran. Participants receive injections every 3 months for 15 to 21 months. The goal is to lower dan…
Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for rare muscle disease: experimental drug enters human trials
Disease control Recruiting nowThis study tests an experimental drug called ARO-DUX4 in people with facioscapulohumeral muscular dystrophy type 1 (FSHD1), a genetic condition that causes muscle weakness. The main goal is to check the drug's safety and how the body processes it. About 60 adults and teens will r…
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New hope for muscle disease: experimental drug ARO-DM1 enters human trials
Disease control Recruiting nowThis study tests a new drug called ARO-DM1 in 78 adults aged 18-65 with type 1 myotonic dystrophy, a genetic muscle disorder. The goal is to check safety and how the body processes the drug. Participants receive either ARO-DM1 or a placebo by IV or injection. It is an early-stage…
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New inhaler aims to calm asthma Flare-Ups
Symptom relief Recruiting nowThis study tests an inhaled medication called ARO-RAGE in 36 adults with mild asthma that is triggered by allergens. The goal is to see if it improves small airway function after breathing in an allergen. Participants will receive either the drug or a placebo and be monitored for…
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC